Immune Response Following BNT162b2 MRNA COVID-19 Vaccination in Pediatric Cancer Patients

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 May 13

PMID 37174028

Authors

K L Juliette Schmidt

Noel M M Dautzenberg

Peter M Hoogerbrugge

Caroline A Lindemans

Stefan Nierkens

Gaby Smits

Rob S van Binnendijk

Louis J Bont

Wim J E Tissing

Affiliations

Soon will be listed here.

Abstract

COVID-19 vaccinations are recommended for children with cancer but data on their vaccination response is scarce. This study assesses the antibody and T-cell response following a 2- or 3-dose vaccination with BNT162b2 mRNA COVID-19 vaccine in children (5-17 years) with cancer. For the antibody response, participants with a serum concentration of anti-SARS-CoV-2 spike 1 antibodies of >300 binding antibody units per milliliter were classified as good responders. For the T-cell response, categorization was based on spike S1 specific interferon-gamma release with good responders having >200 milli-international units per milliliter. The patients were categorized as being treated with chemo/immunotherapy for less than 6 weeks (Tx < 6 weeks) or more than 6 weeks (Tx > 6 weeks) before the first immunization event. In 46 patients given a 2-dose vaccination series, the percentage of good antibody and good T-cell responders was 39.3% and 73.7% in patients with Tx < 6 weeks and 94.4% and 100% in patients with Tx > 6 weeks, respectively. An additional 3rd vaccination in 16 patients with Tx < 6 weeks, increased the percentage of good antibody responders to 70% with no change in T-cell response. A 3-dose vaccination series effectively boosted antibody levels and is of value for patients undergoing active cancer treatment.

Citing Articles

The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria-Tetanus-Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity.

Santi T, Jo J, Harahap A, Werdhani R, Hadinegoro S, SahBandar I Vaccines (Basel). 2024; 12(9).

PMID: 39340062 PMC: 11435621. DOI: 10.3390/vaccines12091032.

COVID-19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T-cells.

Parker R, Le J, Villa M, Luong A, Lin T, Lee Y Int J Cancer. 2024; 155(12):2190-2200.

PMID: 39005114 PMC: 11499007. DOI: 10.1002/ijc.35096.

References

Mavinkurve-Groothuis A, van der Flier M, Stelma F, van Leer-Buter C, Preijers F, Hoogerbrugge P . Absolute lymphocyte count predicts the response to new influenza virus H1N1 vaccination in pediatric cancer patients. Clin Vaccine Immunol. 2012; 20(1):118-21. PMC: 3535770. DOI: 10.1128/CVI.00585-12. View

Den Hartog G, Schepp R, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N . SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis. 2020; 222(9):1452-1461. PMC: 7454740. DOI: 10.1093/infdis/jiaa479. View

Schwarz T, Tober-Lau P, Hillus D, Helbig E, Lippert L, Thibeault C . Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerg Infect Dis. 2021; 27(8):2174-2178. PMC: 8314803. DOI: 10.3201/eid2708.211145. View

Huzly D, Panning M, Smely F, Enders M, Komp J, Falcone V . Accuracy and real life performance of a novel interferon-γ release assay for the detection of SARS-CoV2 specific T cell response. J Clin Virol. 2022; 148:105098. PMC: 8806708. DOI: 10.1016/j.jcv.2022.105098. View

Addo I, Dadzie F, Okeke S, Boadi C, Boadu E . Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. Arch Public Health. 2022; 80(1):200. PMC: 9436729. DOI: 10.1186/s13690-022-00935-x. View

Geers D, Shamier M, Bogers S, Den Hartog G, Gommers L, Nieuwkoop N . SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol. 2021; 6(59). PMC: 9268159. DOI: 10.1126/sciimmunol.abj1750. View

Lehrnbecher T, Sack U, Speckmann C, Groll A, Boldt A, Siebald B . Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer. Clin Infect Dis. 2022; 76(3):e510-e513. PMC: 9384602. DOI: 10.1093/cid/ciac570. View

van den Hoogen L, Smits G, van Hagen C, Wong D, Vos E, van Boven M . Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?. Vaccine. 2022; 40(15):2251-2257. PMC: 8904156. DOI: 10.1016/j.vaccine.2022.03.009. View

Oosting S, van der Veldt A, Fehrmann R, GeurtsvanKessel C, van Binnendijk R, Dingemans A . Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. Lancet Oncol. 2022; 23(7):833-835. PMC: 9236566. DOI: 10.1016/S1470-2045(22)00203-0. View

10.

Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S . Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022; 379:e072141. PMC: 9527398. DOI: 10.1136/bmj-2022-072141. View

11.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

12.

Villeneuve S, Aftandilian C . Neutropenia and Infection Prophylaxis in Childhood Cancer. Curr Oncol Rep. 2022; 24(6):671-686. PMC: 8885776. DOI: 10.1007/s11912-022-01192-5. View

13.

Stich M, Benning L, Speer C, Garbade S, Bartenschlager M, Kim H . Waning Immunity 14 Months After SARS-CoV-2 Infection. Pediatrics. 2022; 150(5). DOI: 10.1542/peds.2022-057151. View

14.

Oosting S, van der Veldt A, GeurtsvanKessel C, Fehrmann R, van Binnendijk R, Dingemans A . mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021; 22(12):1681-1691. PMC: 8577843. DOI: 10.1016/S1470-2045(21)00574-X. View

15.

Bates T, McBride S, Leier H, Guzman G, Lyski Z, Schoen D . Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022; 7(68):eabn8014. PMC: 8939472. DOI: 10.1126/sciimmunol.abn8014. View

16.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

17.

Poparn H, Srichumpuang C, Sosothikul D, Jantarabenjakul W, Lauhasurayotin S, Techavichit P . Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases. Asian Pac J Cancer Prev. 2022; 23(6):2049-2055. PMC: 9587837. DOI: 10.31557/APJCP.2022.23.6.2049. View

18.

Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L, Bezzio S . Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014; 2014:707691. PMC: 4020520. DOI: 10.1155/2014/707691. View

19.

Faura A, Rives S, Lassaletta A, Sebastian E, Madero L, Huerta J . Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatr Blood Cancer. 2020; 67(9):e28557. PMC: 7404582. DOI: 10.1002/pbc.28557. View

20.

Bailey L, Razzaghi H, Burrows E, Bunnell H, Camacho P, Christakis D . Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. JAMA Pediatr. 2020; 175(2):176-184. PMC: 7684518. DOI: 10.1001/jamapediatrics.2020.5052. View